Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Esophageal Squamous Cell Carcinoma 12 Esophageal Neoplasms 9 Uterine Cervical Neoplasms 4 Carcinoma, Non-Small-Cell Lung 3 Squamous Cell Carcinoma of Head and Neck 2 Neoplasm Metastasis 2 Lymphatic Metastasis 2 Uterine Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Thymoma 1 Thymic epithelial tumor 1 Solid Tumor Cancer 1 Recurrence 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Recurrence, Local 1 Nasopharyngeal Carcinoma 1 Mouth Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Ductal, Breast 1 Breast Neoplasms 1

Interventions

ispinesib 2 trifluridine tipiracil drug combination 1 trametinib 1 tipiracil 1 irinotecan sucrosofate 1 Vincristine 1 Trifluridine 1 Temozolomide 1 TP protocol 1 SB 743921 1 Pemetrexed 1 Paclitaxel 1 PE regimen 1 Interleukin-18 1 Immunotherapy 1 Imatinib Mesylate 1 Exercise Therapy 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Solid Tumor Cancer × TP protocol × Clear all

NCT06649448 2024-10-18

EF-001

Shandong Cancer Hospital and Institute

Phase NA Not yet recruiting

Other solid neoplasm

Solid Tumor Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡